The following instructors and speakers have agreed to contribute their expertise to the success of 2021 Skyline Online Course:
 |
Brendan MacLean Brendan worked at Microsoft for 8 years in the 1990s where he was a lead developer and development manager for the Visual C++/Developer Studio Project. Since leaving Microsoft, Brendan has been the Vice President of Engineering for Westside Corporation, Director of Engineering for BEA Systems, Inc., Sr. Software Engineer at the Fred Hutchinson Cancer Research Center, and a founding partner of LakKey Software. In this last position he was one of the key programmers responsible for the Computational Proteomics Analysis System (CPAS), made significant contributions to the development of X!Tandem and the Trans Proteomic Pipeline, and created the LabKey Enterprise Pipeline. Since August, 2008 he has worked as a Sr. Software Engineer within the MacCoss lab and been responsible for all aspects of design, development and support in creating the Skyline Targeted Proteomics Environment and its growing worldwide user community. |
|
 |
Susan Abbatiello Ph.D. Sue received her Ph.D. in analytical chemistry at the University of Florida, and completed a postdoc at the University of Pittsburgh’s Hillman Cancer Center. Susan is currently a Principal Consulting Scientist in Global Research at Waters Corporation. Previously, Susan held positions as the executive director of the MS Core Facility at the Barnett Institute at Northeastern University, and a visiting scientist in the Proteomics Platform at the Broad Institute of MIT and Harvard, and FAIMS Product Manager at Thermo Fisher Scientific. Susan’s research focuses on the development of technology and experiments to measure potential protein biomarkers in cell lines and blood for diseases such as cancer. Susan has co-chaired a committee that is part of the National Cancer Institute’s Clinical Proteomic Technology Assessment for Cancer (CPTAC). |
|
 |
Chris Ashwood Ph.D. |
|
 |
Erin Baker Ph.D.
|
|
 |
Natan Basisty, Ph.D. Nate is a postdoctoral fellow in Dr. Birgit Schilling’s lab in the Buck Institute for Research on Aging in California. He received his Ph.D. from the University of Washington, advised by Drs. Peter Rabinovitch and Michael MacCoss Dr. Basisty develops novel and specialized proteomic approaches to understand aging processes and age-related diseases, including the application of data-independent acquisition (DIA) or SWATH workflows to identify and quantify PTMs and secretomes, development of pipelines to comprehensively assess protein turnover rates, and cell-surface proteomics (surfaceomics). A major aim of his current work is to discover biomarkers of cellular senescence and develop translationally relevant approaches to study senescent cells in humans, enabled by the application of proteomics. Dr. Basisty has been recognized for his work investigating the role of protein turnover in mammalian aging and longevity using a combination of metabolic labeling, LC-MS/MS, and software tools. |
|
 |
Weixian Deng Weixian is a Ph.D. graduate student at UCLA under the supervision of Drs. James Wohlschlegel and Kathrin Plath. He obtained his bachelor and master degrees from Jilin University in China, where he studied using targeted mass spectrometry for quantifying plant protein post translational modifications. In his Ph.D. research, he optimized a series of affinity purification-MS techniques and applied DIA method trying to i) quantify the interactome change of Yamanaka factors in induced pluripotent stem cells (iPSC) reprogramming and ii) to characterize long non-coding RNA (lncRNA) Xist's interactome in early embryo development. His goal is to improve the LC-MS based proteomics to gain better understanding in protein-involved gene regulation molecular events which are usually of low abundance in vivo. |
|
 |
Thomas Lau, Ph.D. Tom is a Senior Research Scientist at Vertex Pharmaceuticals in Boston MA. There he leads efforts for proteomics within chemical biology. He began using mass spectrometry during his PhD research on cancer biomarkers at University College Dublin. Tom has over a decade of experience in proteomics and peptide quantification in both academic and drug discovery settings including previous positions at Celgene, Pfizer and the Broad Institute. His research aims to understand disease mechanisms and advance drug discovery by integrating mass spectrometry and other biological and chemical tools. |
|
 |
Lilian Heil Lilian is a PhD student in Genome Sciences interested in developing methods for the acquisition and analysis of quantitative proteomics data. She joined the department in the fall of 2019 after graduating from the University of North Carolina in the winter of 2018 with a B.S. in Chemistry. Before graduate school, she worked in the Hicks Lab at UNC for 2 years as an undergraduate trainee and for several months as a full time research assistant using mass spectrometry to identify and characterize novel bioactive peptides. There, she helped to discover and sequence a novel antimicrobial peptide from Amaranthus tricolor and developed a passion for mass spectrometry. |
|
 |
Kaylie Kirkwood Kaylie is a second-year graduate student at North Carolina State University working under the advisement of Dr. Erin Baker. Thus far, her research has focused on the development of lipid LC-IMS-MS libraries in Skyline and the application of these libraries to various clinical and environmental applications. Skyline was the first software Kaylie learned to use as an undergraduate researcher for small molecule detection including cyanotoxins, amino acids, and metabolomics profiling of amyotrophic lateral with Dr. David Muddiman. Its adaptability and interactive developers have allowed her to continue utilizing it in her current research. |
|
 |
Christina Ludwig, Ph.D. Tina is heading the proteomics section at the Bavarian Center for Biomolecular Mass Spectrometry (BayBioMS) at the Technical University Munich (www.baybioms.wzw.tum.de). Her current research interests are focused on technical development projects related to targeted and data-independent mass spectrometry, including Selected Reaction Monitoring (SRM), Parallel Reaction Monitoring (PRM) and SWATH-MS. During her postdoc in the laboratory of Professor Ruedi Aebersold at the ETH Zürich Christina was involved in projects aiming for specific site-localization of post-translational modifications and estimation of absolute protein abundances from label-free, targeted mass spectrometric data. |
|
 |
Lindsay K. Pino, Ph.D. Lindsay is a postdoctoral researcher in Dr. Ben Garcia’s lab at the University of Pennsylvania where she uses quantitative mass spectrometry to study epigenetics. Before going to the University of Washington for graduate school, she spent two years in South Korea as a Fulbright scholar and three years working as a research associate in Dr. Steve Carr's Proteomics Platform at the Broad Institute of MIT and Harvard. She earned her PhD under the joint advisorship of Drs. Michael J. MacCoss and William Stafford Noble. There, she developed techniques for data independent acquisition mass spectrometry, in particular the challenges associated with scaling up quantitative mass spectrometry experiments. Her research interests are in the roles proteins play in nuclear organization and the maintenance of genomic stability. |
|
 |
Nick Riley, Ph.D. Nick is a postdoctoral researcher in Prof. Carolyn Bertozzi’s lab at Stanford University, where he is developing glycoproteomics tools to understand how cancer cells alter their cell surface glycoproteome to promote metastasis. Before Stanford, Nick earned his Ph.D. with Prof. Josh Coon at the University of Wisconsin-Madison. There he worked on mass spectrometry instrumentation and methodology to improve the characterization of both peptides and intact proteins. Most of his efforts focused on implementing activated ion electron transfer dissociation (AI-ETD) to improve sequencing information obtained from ETD MS/MS spectra, which ultimately led him to the intriguing world of glycobiology that he now studies in the Bertozzi group. |
|
 |
Julia Robbins Julia attended the University of Washington, graduating in 2018 with a BS in Biology. Under the tutelage of her many professors, Julia obtained an approximate knowledge of many biological concepts and an acute knowledge of approximately none (except perhaps invertebrate zoology). She began working in the MacCoss lab in January 2018, and her current focus is Alzheimer's Disease research in mice models and humans. Along with the freelance graphic design and scientific illustration she does on the side, she also designed and maintains the MacCoss lab website. |
|
 |
Juan Rojas Juan is a third-year Ph.D. student at Universität Leipzig under the tutelage of Prof. Dr. Ralf Hoffmann where he uses LC-IMS-MS to identify and quantify low abundance carbonylation PTMs in human plasma in search of potential biomarkers towards oxidative distress related diseases such as rheumatoid arthritis. During his study, comprehensive platforms, such as Skyline, that can integrate LC-IMS-MS and peptide identifications from multiple search engines have become indispensable for the progress of carbonylation PTMs. Prior to his stay in Leipzig (Germany), this Panamanian-born nomad obtained a BSc in Biochemistry at Florida State University (USA), worked as a mass spectrometry technician at INDICASAT-AIP (Panama), and obtained a MSc in Molecular Analytical Science at The University of Warwick (UK). |
|
 |
Roman Sakson works as a research associate at the Leibniz Institute for Analytical Sciences, ISAS, in Dortmund (Germany). He joined the Proteomics group headed by Prof. Albert Sickmann end of 2020. Before that, Roman worked for five years as a master as well as Ph.D. student at the Core Facility for MS and Proteomics at Heidelberg University. In 2015 Roman started working with Skyline and later Panorama for targeted assay development, data visualization and quality control. He enjoys teaching a lot and has offered Skyline courses to colleagues and fellow students on numerous occasions. Roman’s main current research interest is robust and accurate targeted proteomics for clinical applications. | |
 |
Stoyan Stoychev, Ph.D. Stoyan currently holds a joint position as a senior researcher at the CSIR Molecular Diagnostics & Omics group (Pretoria, South Africa) as well as Head of Proteomics at ReSyn Biosciences. He started his career in 2008 as a post-doctoral researcher with the task of establishing mass spectrometry analytical facility after completing a Ph.D. in Structural Biology. Currently the main focus of this unit is the application of high-throughput DIA workflows in the space of clinical proteomics. The facility is part of the Diplomics network of academic, commercial and industrial labs supporting Oimcs research in South Africa. At ReSyn Stoyan is involved in the development of technology, products and wokflows focussed on bioseparation and mass spectrometry sample preparation. Stoyan has won numerous awards including two Technical excellence as well as a Team Impact award. |
|
 |
J. Will Thompson, Ph.D. Will is the Assistant Director of the Duke Proteomics and Metabolomics Shared Resource, and Assistant Research Professor in the Department of Pharmacology and Cancer Biology. He received his Ph.D. in Ultrahigh Pressure Liquid Chromatography from the laboratory of Dr. Jim Jorgenson at the University of North Carolina at Chapel Hill, and subsequently joined the Disease and Biomarker Proteomics group led by Dr. Arthur Moseley at GlaxoSmithKline. In 2007, Dr. Thompson assisted Dr. Moseley in founding the Duke Proteomics Core Facility, which as of winter 2017 has 10 full time scientists. Dr. Thompson has overseen the expansion of the group's efforts into small molecule and metabolomics analysis, which now represents roughly 40% of the work of the Shared Resource. His research in part focuses on application of novel proteomics and targeted metabolomics assays to clinical and basic science research applications, with special emphasis on Alzheimer's Disease. The Core has completed over 1200 projects for nearly 200 principal investigators since 2007, and works with investigators both inside and outside the Duke School of Medicine. |